BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reubi JC, Schonbrunn A. Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends Pharmacol Sci 2013;34:676-88. [PMID: 24183675 DOI: 10.1016/j.tips.2013.10.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Carr HS, Chang JT, Frost JA. The PDZ Domain Protein SYNJ2BP Regulates GRK-Dependent Sst2A Phosphorylation and Downstream MAPK Signaling. Endocrinology 2021;162:bqaa229. [PMID: 33313679 DOI: 10.1210/endocr/bqaa229] [Reference Citation Analysis]
2 Waser B, Blank A, Karamitopoulou E, Perren A, Reubi JC. Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas. Mod Pathol 2015;28:391-402. [DOI: 10.1038/modpathol.2014.113] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 6.5] [Reference Citation Analysis]
3 Hartig SM, Cox AR. Paracrine signaling in islet function and survival. J Mol Med (Berl) 2020;98:451-67. [PMID: 32067063 DOI: 10.1007/s00109-020-01887-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
4 Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Immunostimulatory cytokines in cancer therapy. Oncoimmunology 2014;3:e29030. [PMID: 25083328 DOI: 10.4161/onci.29030] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
5 Basu S, Parghane RV, Kamaldeep, Chakrabarty S. Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors. Seminars in Nuclear Medicine 2020;50:447-64. [DOI: 10.1053/j.semnuclmed.2020.05.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
6 Caplin ME. Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients? EJC Suppl 2021;16:1-4. [PMID: 34912477 DOI: 10.1016/j.ejcsup.2021.06.001] [Reference Citation Analysis]
7 Escala Cornejo RA, García-Talavera P, Navarro Martin M, Pérez López B, García Muñoz M, Tamayo Alonso MP, Cruz Hernández JJ. Large cell neuroendocrine carcinoma of the lung with atypical evolution and a remarkable response to lutetium Lu 177 dotatate. Ann Nucl Med 2018;32:568-72. [PMID: 30051167 DOI: 10.1007/s12149-018-1276-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
8 Appay R, Tabouret E, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D; POLA network. Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome. Acta Neuropathol Commun 2018;6:89. [PMID: 30193580 DOI: 10.1186/s40478-018-0594-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
9 Fisher MD, Pulgar S, Kulke MH, Mirakhur B, Miller PJ, Walker MS, Schwartzberg LS. Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database. J Gastrointest Cancer 2019;50:816-23. [PMID: 30121904 DOI: 10.1007/s12029-018-0160-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
10 Kaemmerer D, Specht E, Sänger J, Wirtz RM, Sayeg M, Schulz S, Lupp A. Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers. J Clin Endocrinol Metab 2015;100:831-40. [PMID: 25494861 DOI: 10.1210/jc.2014-2699] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
11 Pedraza-Arevalo S, Ibáñez-Costa A, Blázquez-Encinas R, Branco MR, Vázquez-Borrego MC, Herrera-Martínez AD, Venegas-Moreno E, Serrano-Blanch R, Arjona-Sánchez Á, Gálvez-Moreno MA, Korbonits M, Soto-Moreno A, Gahete MD, Charalambous M, Luque RM, Castaño JP. Epigenetic and post-transcriptional regulation of somatostatin receptor subtype 5 (SST5 ) in pituitary and pancreatic neuroendocrine tumors. Mol Oncol 2021. [PMID: 34601790 DOI: 10.1002/1878-0261.13107] [Reference Citation Analysis]
12 Ma MT, Cullinane C, Waldeck K, Roselt P, Hicks RJ, Blower PJ. Rapid kit-based (68)Ga-labelling and PET imaging with THP-Tyr(3)-octreotate: a preliminary comparison with DOTA-Tyr(3)-octreotate. EJNMMI Res 2015;5:52. [PMID: 26452495 DOI: 10.1186/s13550-015-0131-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
13 Wu F, Song G, de Graaf C, Stevens RC. Structure and Function of Peptide-Binding G Protein-Coupled Receptors. J Mol Biol 2017;429:2726-45. [PMID: 28705763 DOI: 10.1016/j.jmb.2017.06.022] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
14 Qian ZR, Li T, Ter-Minassian M, Yang J, Chan JA, Brais LK, Masugi Y, Thiaglingam A, Brooks N, Nishihara R, Bonnemarie M, Masuda A, Inamura K, Kim SA, Mima K, Sukawa Y, Dou R, Lin X, Christiani DC, Schmidlin F, Fuchs CS, Mahmood U, Ogino S, Kulke MH. Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors. Pancreas 2016;45:1386-93. [PMID: 27622342 DOI: 10.1097/MPA.0000000000000700] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 10.5] [Reference Citation Analysis]
15 Mikołajczyk A, Złotkowska D. Subclinical Lipopolysaccharide from Salmonella Enteritidis Induces Dysregulation of Bioactive Substances from Selected Brain Sections and Glands of Neuroendocrine Axes. Toxins (Basel) 2019;11:E91. [PMID: 30717384 DOI: 10.3390/toxins11020091] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
16 Heidarpour M, Shafie D, Aminorroaya A, Sarrafzadegan N, Farajzadegan Z, Nouri R, Najimi A, Dimopolou C, Stalla G. Effects of somatostatin analog treatment on cardiovascular parameters in patients with acromegaly: A systematic review. J Res Med Sci 2019;24:29. [PMID: 31143230 DOI: 10.4103/jrms.JRMS_955_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Fathi S, Oyelere AK. Liposomal drug delivery systems for targeted cancer therapy: is active targeting the best choice? Future Med Chem 2016;8:2091-112. [PMID: 27774793 DOI: 10.4155/fmc-2016-0135] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
18 Pedraza-Arévalo S, Gahete MD, Alors-Pérez E, Luque RM, Castaño JP. Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors. Rev Endocr Metab Disord 2018;19:179-92. [PMID: 30293213 DOI: 10.1007/s11154-018-9465-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
19 Lhenry D, Larrouy M, Bernhard C, Goncalves V, Raguin O, Provent P, Moreau M, Collin B, Oudot A, Vrigneaud J, Brunotte F, Goze C, Denat F. BODIPY: A Highly Versatile Platform for the Design of Bimodal Imaging Probes. Chem Eur J 2015;21:13091-9. [DOI: 10.1002/chem.201501676] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
20 De Luca S, Fonti R, Camera L, Salvatore B, Faggiano A, Ciarmiello A, Segreto S, Colao A, Salvatore M, Del Vecchio S. Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma. Ann Nucl Med 2016;30:234-41. [PMID: 26753628 DOI: 10.1007/s12149-015-1056-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
21 Olsen C, Memarzadeh K, Ulu A, Carr HS, Bean AJ, Frost JA. Regulation of Somatostatin Receptor 2 Trafficking by C-Tail Motifs and the Retromer. Endocrinology 2019;160:1031-43. [PMID: 30822353 DOI: 10.1210/en.2018-00865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
22 Naraev BG, Halland M, Halperin DM, Purvis AJ, OʼDorisio TM, Halfdanarson TR. Management of Diarrhea in Patients With Carcinoid Syndrome. Pancreas 2019;48:961-72. [PMID: 31425482 DOI: 10.1097/MPA.0000000000001384] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
23 Exner S, Schuldt C, Sachindra S, Du J, Heing-Becker I, Licha K, Wiedenmann B, Grötzinger C. AGTR1 Is Overexpressed in Neuroendocrine Neoplasms, Regulates Secretion and May Potentially Serve as a Target for Molecular Imaging and Therapy. Cancers (Basel) 2020;12:E3138. [PMID: 33120925 DOI: 10.3390/cancers12113138] [Reference Citation Analysis]
24 Torniai M, Scortichini L, Tronconi F, Rubini C, Morgese F, Rinaldi S, Mazzanti P, Berardi R. Systemic treatment for lung carcinoids: from bench to bedside. Clin Transl Med 2019;8:22. [PMID: 31273555 DOI: 10.1186/s40169-019-0238-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
25 Rorsman P, Huising MO. The somatostatin-secreting pancreatic δ-cell in health and disease. Nat Rev Endocrinol 2018;14:404-14. [PMID: 29773871 DOI: 10.1038/s41574-018-0020-6] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 23.7] [Reference Citation Analysis]
26 Yu R, Wachsman A. Imaging of Neuroendocrine Tumors: Indications, Interpretations, Limits, and Pitfalls. Endocrinol Metab Clin North Am 2017;46:795-814. [PMID: 28760239 DOI: 10.1016/j.ecl.2017.04.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
27 Vesterinen T, Leijon H, Mustonen H, Remes S, Knuuttila A, Salmenkivi K, Vainio P, Arola J, Haglund C. Somatostatin Receptor Expression Is Associated With Metastasis and Patient Outcome in Pulmonary Carcinoid Tumors. The Journal of Clinical Endocrinology & Metabolism 2019;104:2083-93. [DOI: 10.1210/jc.2018-01931] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
28 Reubi JC. In Vitro Evaluation of Molecular Tumor Targets in Nuclear Medicine: Immunohistochemistry Is One Option, but Under Which Conditions? J Nucl Med 2017;58:1885-7. [PMID: 28912151 DOI: 10.2967/jnumed.117.197582] [Reference Citation Analysis]
29 Gatto F, Barbieri F, Arvigo M, Thellung S, Amarù J, Albertelli M, Ferone D, Florio T. Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms. Int J Mol Sci 2019;20:E3940. [PMID: 31412614 DOI: 10.3390/ijms20163940] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
30 Hernandez Vargas S, Kossatz S, Voss J, Ghosh SC, Tran Cao HS, Simien J, Reiner T, Dhingra S, Fisher WE, Azhdarinia A. Specific Targeting of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery. Clin Cancer Res 2019;25:4332-42. [PMID: 31015345 DOI: 10.1158/1078-0432.CCR-18-3312] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
31 Saif MW, Fu J, Smith MH, Weinstein B, Relias V, Daly KP. Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors. J Pancreat Cancer 2018;4:64-71. [PMID: 30788459 DOI: 10.1089/pancan.2018.0013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Rana A, Bhatnagar S. Advancements in folate receptor targeting for anti-cancer therapy: A small molecule-drug conjugate approach. Bioorg Chem 2021;112:104946. [PMID: 33989916 DOI: 10.1016/j.bioorg.2021.104946] [Reference Citation Analysis]
33 Mohamed A, Blanchard MP, Albertelli M, Barbieri F, Brue T, Niccoli P, Delpero JR, Monges G, Garcia S, Ferone D, Florio T, Enjalbert A, Moutardier V, Schonbrunn A, Gerard C, Barlier A, Saveanu A. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures. Endocr Relat Cancer 2014;21:691-704. [PMID: 25012983 DOI: 10.1530/ERC-14-0086] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
34 Heing-Becker I, Grötzinger C, Beindorff N, Prasad S, Erdmann S, Exner S, Haag R, Licha K. A Cyanine-Bridged Somatostatin Hybrid Probe for Multimodal SSTR2 Imaging in Vitro and in Vivo: Synthesis and Evaluation. Chembiochem 2021;22:1307-15. [PMID: 33238069 DOI: 10.1002/cbic.202000791] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Maina T, Cescato R, Waser B, Tatsi A, Kaloudi A, Krenning EP, de Jong M, Nock BA, Reubi JC. [ 111 In-DOTA]LTT-SS28, a First Pansomatostatin Radioligand for in Vivo Targeting of Somatostatin Receptor-Positive Tumors. J Med Chem 2014;57:6564-71. [DOI: 10.1021/jm500581d] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
36 Alshafie W, Pan YE, Kreienkamp HJ, Stroh T. Characterization of agonist-dependent somatostatin receptor subtype 2 trafficking in neuroendocrine cells. Endocrine 2020;69:655-69. [PMID: 32383089 DOI: 10.1007/s12020-020-02329-x] [Reference Citation Analysis]
37 Srinivasarao M, Galliford CV, Low PS. Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat Rev Drug Discov 2015;14:203-19. [DOI: 10.1038/nrd4519] [Cited by in Crossref: 402] [Cited by in F6Publishing: 371] [Article Influence: 57.4] [Reference Citation Analysis]
38 Xu J. Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs). Ther Adv Med Oncol 2021;13:17588359211042689. [PMID: 34484432 DOI: 10.1177/17588359211042689] [Reference Citation Analysis]
39 Owonikoko TK, Zhang G, Lallani SB, Chen Z, Martinson DE, Khuri FR, Lonial S, Marcus A, Sun SY. Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models. PLoS One 2019;14:e0206309. [PMID: 30807575 DOI: 10.1371/journal.pone.0206309] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
40 Nelson CA, Azure MT, Adams CT, Zinn KR. The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts. J Nucl Med 2014;55:2020-5. [PMID: 25359879 DOI: 10.2967/jnumed.114.140780] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
41 Vitali E, Cambiaghi V, Zerbi A, Carnaghi C, Colombo P, Peverelli E, Spada A, Mantovani G, Lania AG. Filamin-A is required to mediate SST2 effects in pancreatic neuroendocrine tumours. Endocr Relat Cancer 2016;23:181-90. [PMID: 26733502 DOI: 10.1530/ERC-15-0358] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
42 Kidd M, Modlin IM, Bodei L, Drozdov I. Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology. Cell Mol Gastroenterol Hepatol 2015;1:131-53. [PMID: 28210673 DOI: 10.1016/j.jcmgh.2014.12.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
43 Crabtree JS. Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy. Front Endocrinol (Lausanne) 2017;8:341. [PMID: 29255447 DOI: 10.3389/fendo.2017.00341] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
44 Cioppi F, Cianferotti L, Masi L, Giusti F, Brandi ML. The LARO-MEN1 study: a longitudinal clinical experience with octreotide Long-Acting Release in patients with Multiple Endocrine Neoplasia type 1 Syndrome. Clin Cases Miner Bone Metab 2017;14:123-30. [PMID: 29263719 DOI: 10.11138/ccmbm/2017.14.1.123] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
45 Wémeau JL. Therapeutic innovations in endocrine diseases - Part 4 : Pasireotide: Long-acting release somatostatin analogue. Presse Med 2016;45:e217-20. [PMID: 27242210 DOI: 10.1016/j.lpm.2016.05.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
46 Gatto F, Biermasz NR, Feelders RA, Kros JM, Dogan F, van der Lely AJ, Neggers SJ, Lamberts SW, Pereira AM, Ferone D, Hofland LJ. Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. Eur J Endocrinol 2016;174:651-62. [PMID: 26888629 DOI: 10.1530/EJE-15-0391] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
47 Behnammanesh H, Jokar S, Erfani M, Geramifar P, Sabzevari O, Amini M, Mazidi SM, Hajiramezanali M, Beiki D. Design, preparation and biological evaluation of a 177Lu-labeled somatostatin receptor antagonist for targeted therapy of neuroendocrine tumors. Bioorganic Chemistry 2020;94:103381. [DOI: 10.1016/j.bioorg.2019.103381] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
48 Khan M, Spicer J. The Evolving Landscape of Cancer Therapeutics. In: Barrett JE, Page CP, Michel MC, editors. Concepts and Principles of Pharmacology. Cham: Springer International Publishing; 2019. pp. 43-79. [DOI: 10.1007/164_2019_312] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
49 Castellano D, Grande E, Valle J, Capdevila J, Reidy-lagunes D, O’connor JM, Raymond E. Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors. Cancer Chemother Pharmacol 2015;75:1099-114. [DOI: 10.1007/s00280-014-2642-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
50 Krug S, Mordhorst JP, Moser F, Theuerkorn K, Ruffert C, Egidi M, Rinke A, Gress TM, Michl P. Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells. PLoS One 2019;14:e0218953. [PMID: 31237925 DOI: 10.1371/journal.pone.0218953] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
51 Cives M, Strosberg J. The Expanding Role of Somatostatin Analogs in Gastroenteropancreatic and Lung Neuroendocrine Tumors. Drugs 2015;75:847-58. [DOI: 10.1007/s40265-015-0397-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
52 Gadelha MR, Wildemberg LE, Bronstein MD, Gatto F, Ferone D. Somatostatin receptor ligands in the treatment of acromegaly. Pituitary 2017;20:100-8. [DOI: 10.1007/s11102-017-0791-0] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 10.0] [Reference Citation Analysis]
53 Saif MW. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Opinion on Pharmacotherapy 2016;17:443-56. [DOI: 10.1517/14656566.2016.1127914] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
54 Fuentes-fayos AC, García-martínez A, Herrera-martínez AD, Jiménez-vacas JM, Vázquez-borrego MC, Castaño JP, Picó A, Gahete MD, Luque RM. Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors. Minerva Endocrinol 2019;44. [DOI: 10.23736/s0391-1977.19.02970-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 4.7] [Reference Citation Analysis]
55 Ghosh SC, Rodriguez M, Carmon KS, Voss J, Wilganowski NL, Schonbrunn A, Azhdarinia A. A Modular Dual-Labeling Scaffold That Retains Agonistic Properties for Somatostatin Receptor Targeting. J Nucl Med 2017;58:1858-64. [PMID: 28572490 DOI: 10.2967/jnumed.116.187971] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]